Loading stock data…
$3.18+0.02 (+0.63%)
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
Nasus Pharma Ltd. in the Healthcare sector is trading at $3.18 with a market capitalization of $37M. Wall Street consensus targets $19.67 (3 analysts), implying a +518.4% move over the next 12 months. The stock is currently near its 52-week low of $1.98, remaining 18.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public...